Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Race Hots Up For EMA After Brexit

Executive Summary

France has officially named Lille as the city it would like to host the European Medicines Agency once the UK leaves the EU, and Italy has appointed an ambassador to promote Milan’s bid for the agency. Meanwhile, stakeholders in Denmark are joining forces to stress why Copenhagen would be a good choice, and Ireland, the Netherlands and Austria have all confirmed their candidacies.

You may also be interested in...



Quest For ‘It Factor’ Continues In Competition For EMA After Brexit

The many cities that want to host the European Medicines Agency when it moves from London to another member state in light of Brexit are working hard to come up with a determining factor that will make them the obvious choice. It may on the surface seem strange, but Ireland is making much of the fact that if its capital city Dublin were chosen, existing EMA staff wouldn’t need to move there.

Rasi On Brexit: ‘EMA Is Well-Oiled Machine That We Cannot Afford To Start Stuttering’

European Medicines Agency head Guido Rasi tackles issue of Brexit in agency’s 2016 annual report, saying EMA is “core building block of the common market for medicines in the EU” that operates like “well-oiled machinery.”

Ireland Promotes Dublin As ‘Natural Destination For EMA’ After Brexit

Ireland is promoting Dublin as the new natural home of the European Medicines Agency when the agency relocates from London after Brexit. It cites the “excellent existing relationship” the country’s regulator, the HPRA, has with the EMA and with the broader EU medicines regulatory network, and the fact that the HPRA doesn’t only regulate medicines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel